Publikasi Scopus FKUI 2021 per tanggal 31 Oktober 2021 (739 artikel)

Uchihara Y., Permata T.B.M., Sato H., Shibata A.
57221723636;57197808751;55697961900;8323572900;
Modulation of immune responses by DNA damage signaling
2021
DNA Repair
104
103135
Signal Transduction Program, Gunma University Initiative for Advanced Research (GIAR), Gunma UniversityGunma, Japan; Department of Radiation Oncology, Faculty of Medicine Universitas Indonesia, Dr. Cipto Mangunkusumo Hospital, Jakarta, 10430, Indonesia; Department of Radiation Oncology, Gunma University, Gunma, Japan
Uchihara, Y., Signal Transduction Program, Gunma University Initiative for Advanced Research (GIAR), Gunma UniversityGunma, Japan; Permata, T.B.M., Department of Radiation Oncology, Faculty of Medicine Universitas Indonesia, Dr. Cipto Mangunkusumo Hospital, Jakarta, 10430, Indonesia; Sato, H., Department of Radiation Oncology, Gunma University, Gunma, Japan; Shibata, A., Signal Transduction Program, Gunma University Initiative for Advanced Research (GIAR), Gunma UniversityGunma, Japan
An accumulation of evidence indicates the importance of DNA damage signaling in modulating immune responses. Indeed, understanding the mechanism that underlies signal transduction originating from DNA damage is vital to overcoming refractory cancer, particularly when cancer immune therapy is applied in combination with DNA damage-dependent radio/chemotherapy. In addition, immune-associated responses to such signals can aggravate the symptoms of infections, allergies, autoimmune disease, and aging. In this review, we discuss how cells transduce signals, triggered by DNA damage, from their origins to neighboring cells and how this affects immune and inflammatory responses. ? 2021 Elsevier B.V.
Cancer therapy; DNA damage signaling; Immune crosstalk; Immune-associated disease; Inflammation
nucleic acid; Article; cancer immunotherapy; DNA damage response; down regulation; human; immune response; immunomodulation; immunopathology; immunoregulation; inflammation; priority journal; signal transduction
Elsevier B.V.
15687864
34029876
Article
Q1
2359
1004